BMS 986166 is an experimental drug being developed
by Bristol-Myers Squibb for treating Ulcerative Colitis (UC). Ulcerative
colitis (UC) is a long-term condition that results in inflammation and ulcers
of the colon and rectum. The primary symptom of active disease is abdominal
pain and diarrhea mixed with blood. Weight loss, fever, and anemia may also
occur. The cause of UC is unknown. Theories involve immune system dysfunction,
genetics, changes in the normal gut bacteria, and environmental factors.
Dietary changes may improve symptoms. Several medications are used to treat
symptoms and bring about and maintain remission. These include aminosalicylates
such as sulfasalazine, steroids, immunosuppressants such as azathioprine, and
biological therapy. Removal of the colon by surgery may be necessary if the
disease is severe.
 |
| New Drug for Treating Ulcerative Colitis |
Preclinical
development is ongoing, and Phase I development of an oral solution of BMS
986166 is planned in the US [1].
References:
1. ClinicalTrials.gov
A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in
Healthy Volunteers. NCT03038711
